Skip to main content
Article thumbnail
Location of Repository

Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD

By Shironjit K. Saha, C. Doe, V. Mistry, S. Siddiqui, D. Parker, M. Sleeman, E. S. Cohen and Christopher E. Brightling


Background: Granulocyte–macrophage colony-stimulating factor (GM-CSF) has been implicated as an important mediator in the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD). However, the expression of GM-CSF and its receptor in airway samples in asthma and COPD across disease severity needs to be further defined. Methods: Sputum GM-CSF was measured in 18 control subjects, 45 subjects with asthma and 47 subjects with\ud COPD. Enumeration of GM-CSF+ cells in the bronchial\ud submucosa and airway smooth muscle bundle was\ud performed in 29 control subjects, 36 subjects with\ud asthma and 10 subjects with COPD.\ud Results: The proportion of subjects with measurable GMCSF\ud in the sputum was raised in those with moderate (7/\ud 14) and severe (11/18) asthma, and in those with COPD\ud GOLD (Global Initiative for Chronic Obstructive Lung\ud Disease) stage II (7/16), III (8/17) and IV (7/14) compared\ud with controls (1/18) and those with mild asthma (0/13);\ud p=0.001. The sputum GM-CSF concentration was\ud correlated with the sputum eosinophilia in subjects with\ud moderate to severe asthma (rs=0.41; p=0.018). The\ud median (interquartile range) GM-CSF+ and GM-CSFR+\ud cells/mm2 of submucosa was increased in severe asthma\ud (1.4 (3.0) and 2.1 (8.4)) compared with those with mild to\ud moderate asthma (0 (2.5) and 1.1 (5)) and healthy\ud controls (0 (0.5) and 0 (1.6)), (p=0.004 and p=0.02,\ud respectively).\ud Conclusions: The findings support a potential role for\ud GM-CSF in asthma and COPD and suggest that overexpression\ud of GM-CSF in sputum and the bronchial\ud mucosa is a particular feature of severe asthma

Publisher: BMJ Publishing Group
Year: 2009
DOI identifier: 10.1136/thx.2008.108290
OAI identifier:

Suggested articles


  1. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. doi
  2. (2002). Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte–macrophage colonystimulating factor (GM-CSF). Cell Immunol doi
  3. Brightling CE. Eosinophilic airway inflammation in COPD. doi
  4. (2003). Bronchial hyperresponsiveness and airway inflammation in adolescents with asymptomatic childhood asthma. Allergy doi
  5. (1992). Cytokines in symptomatic asthma airways. doi
  6. (2003). Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax doi
  7. (1988). Effects of granulocyte–macrophage colonystimulating factor and colony-stimulating factor-1 on the proliferation and differentiation of murine alveolar macrophages.
  8. (1991). Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. doi
  9. (2004). Endobronchial Biopsy workshop. Methods for the assessment of endobronchial biopsies in clinical research: application to studies of pathogenesis and the effects of treatment. doi
  10. Endocytic internalization of adenovirus, nonspecific phagocytosis, and cytoskeletal organization are coordinately regulated in alveolar macrophages by GM-CSF and PU.1. doi
  11. Eosinophils in asthma and other allergic diseases. doi
  12. (2008). Global Initiative for Asthma Guidelines 11/06. Available at: www.ginasthma. com (accessed 1
  13. (1991). Glucocorticoids inhibit eosinophil responses to granulocyte–macrophage colony-stimulating factor.
  14. GM-CSF autoantibodies and neutrophil dysfunction in primary pulmonary alveolar proteinosis. doi
  15. (2008). GOLD—the Global initiative for chronic Ostructive Long Disease. Available at: (accessed 1
  16. Granulocyte–macrophage colony-stimulating factor is required for bronchial eosinophilia in a murine model of allergic airway inflammation. doi
  17. (1995). Granulocyte–macrophage colonystimulating factor increases 5-lipoxygenase gene transcription and protein expression in human neutrophils.
  18. (1994). Granulocyte–macrophage colonystimulating factor, eosinophils and eosinophil cationic protein in subjects with and without mild, stable, atopic asthma. doi
  19. Granulocyte/macrophage colony-stimulating factor autoantibodies and myeloid cell immune fnctions in healthy subjects. doi
  20. Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo. doi
  21. Guidelines for methacholine and exercise challenge testing—1999.
  22. (1993). Immunohistochemistry on resin sections: a comparison of resin embedding techniques for small mucosal biopsies. Biotech Histochem doi
  23. (2008). Information System. World Health Statistics
  24. Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralisation of GM-CSF via repression of TLR- doi
  25. Mast-cell infiltration of airway smooth muscle in asthma. doi
  26. Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. doi
  27. Optimized dialysis and protease inhibition of sputum dithiothreitol supernatants. doi
  28. (2004). Physiol Lung Cell Mol Physiol doi
  29. (2006). Profiles of proinflammatory cytokines in sputum from different groups of severe asthmatic patients. Ann Allergy Asthma Immunol doi
  30. (1999). Receptor clearance obscures the magnitude of granulocyte–macrophage colony-stimulating factor responses in mice to endotoxin or local infections. Blood
  31. Severe asthma in adults: what are the important questions?
  32. Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2008;63(Suppl 4):iv1–121. doi
  33. (2002). Standardised methodology of sputum induction and processing. doi
  34. The structure of the GM-CSFR receptor complex reveals a distinct mode of cytokine receptor activation. doi
  35. (1997). The use of induced sputum to investigate airway inflammation. Thorax doi
  36. (2006). Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophagecolony stimulating factor (GM-CSF). Pharmacol Ther doi
  37. Thoracic Society Bronchoscopy Guidelines Committee, a Subcommittee of the Standards of Care Committee of the British Thoracic Society. British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax 2001;56(Suppl 1):i1–21. doi
  38. (1997). Upregulation of alpha GM-CSFreceptor in nonatopic asthma but not in atopic asthma. doi
  39. Validation of assays for inflammatory mediators in sputum. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.